HK Stock Market Move | ZAI LAB (09688) up more than 8% as the new indication for Ripretinib is expected to be included in priority review

ZAI LAB (09688) rose more than 8%, rising 8.29% to HK$22.85 as of the time of writing, with a trading volume of HK$54.31 million. On the news front, on February 12, the official website of the Drug Evaluation Center of the China National Medical Products Administration (NMPA) showed that ZAI LAB's application for the priority review of its Repotrectinib capsules, intended for adult patients with NTRK fusion gene positive solid tumors, is under consideration. Public information indicates that Repotrectinib is a new generation tyrosine kinase inhibitor (TKI) targeting the ROS1 oncogene, with ZAI LAB holding exclusive development and commercialization rights for the product in Greater China. It is reported that Repotrectinib was approved by the FDA in November 2023 for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adult patients, and was approved for marketing by the Chinese NMPA in May 2024 for use in adult patients with locally advanced or metastatic non-small cell lung cancer who are ROS1-positive.